Literature DB >> 18445228

Functional analysis of human CNGA3 mutations associated with colour blindness suggests impaired surface expression of channel mutants A3(R427C) and A3(R563C).

Katja Koeppen1, Peggy Reuter, Susanne Kohl, Britta Baumann, Thomas Ladewig, Bernd Wissinger.   

Abstract

Mutations in the CNGA3 gene have been associated with complete and incomplete forms of total colour blindness (achromatopsia), a disorder characterized by reduced visual acuity, lack of colour discrimination, photophobia and nystagmus. CNGA3 encodes the A-subunit of the cone photoreceptor cyclic nucleotide-gated (CNG) channel, an essential component of the phototransduction cascade. Here we report the identification of three new CNGA3 mutations in patients with achromatopsia. To assess the pathogenicity of these newly identified and four previously reported mutations, mutant CNGA3 channels were heterologously expressed in a human embryonic kidney cell line (HEK293 cells) and functionally analysed using calcium imaging. Channels with the mutations R427C and R563C showed a response in imaging experiments and were subsequently characterized in-depth with the patch-clamp technique. The mutant channels were analysed as homooligomers and also as heterooligomers with the wild-type B-subunit present in native channels. Overall, cyclic guanosine monophosphate (cGMP) maximum currents of mutant channels were profoundly reduced in homo- and heteromers. Treatment with the chemical chaperone glycerol effectively increased macroscopic currents, presumably by enhancing surface expression of mutant channels as confirmed by immunocytochemistry. These results suggest decreased channel density in the cell membrane due to impaired folding or trafficking of the channel protein as the main pathogenic effect of the mutations R427C and R563C. Moreover, A3(R427C) homomers showed distinctly increased cGMP and cyclic adenosine monophosphate (cAMP) sensitivities as well as cAMP fractional currents that were raised to over 90% of cGMP maximum currents. Co-expression of A3(R427C) with the B3 subunit compensated for most of these aberrant properties, apart from the reduced cGMP maximum currents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18445228     DOI: 10.1111/j.1460-9568.2008.06195.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  14 in total

1.  Genetic analysis of four Pakistani families with achromatopsia and a novel S4 motif mutation of CNGA3.

Authors:  Muhammad Arif Nadeem Saqib; Bilal Malik Awan; Mehwish Sarfraz; Muhammad Nasim Khan; Sajid Rashid; Muhammad Ansar
Journal:  Jpn J Ophthalmol       Date:  2011-09-13       Impact factor: 2.447

2.  The disease-causing mutations in the carboxyl terminus of the cone cyclic nucleotide-gated channel CNGA3 subunit alter the local secondary structure and interfere with the channel active conformational change.

Authors:  Alexander V Matveev; J Browning Fitzgerald; Jianhua Xu; Anna P Malykhina; Karla K Rodgers; Xi-Qin Ding
Journal:  Biochemistry       Date:  2010-03-02       Impact factor: 3.162

3.  Homozygous missense variant in the human CNGA3 channel causes cone-rod dystrophy.

Authors:  Rehan S Shaikh; Peggy Reuter; Robert A Sisk; Tasleem Kausar; Mohsin Shahzad; Muhammad I Maqsood; Ateeq Yousif; Muhammad Ali; Saima Riazuddin; Bernd Wissinger; Zubair M Ahmed
Journal:  Eur J Hum Genet       Date:  2014-07-23       Impact factor: 4.246

4.  Achromatopsia caused by novel missense mutations in the CNGA3 gene.

Authors:  Xi-Teng Chen; Hui Huang; Yan-Hua Chen; Li-Jie Dong; Xiao-Rong Li; Xiao-Min Zhang
Journal:  Int J Ophthalmol       Date:  2015-10-18       Impact factor: 1.779

5.  Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy.

Authors:  Livia S Carvalho; Jianhua Xu; Rachael A Pearson; Alexander J Smith; James W Bainbridge; Lynsie M Morris; Steven J Fliesler; Xi-Qin Ding; Robin R Ali
Journal:  Hum Mol Genet       Date:  2011-05-15       Impact factor: 6.150

6.  Accessory heterozygous mutations in cone photoreceptor CNGA3 exacerbate CNG channel-associated retinopathy.

Authors:  Markus Burkard; Susanne Kohl; Timm Krätzig; Naoyuki Tanimoto; Christina Brennenstuhl; Anne E Bausch; Katrin Junger; Peggy Reuter; Vithiyanjali Sothilingam; Susanne C Beck; Gesine Huber; Xi-Qin Ding; Anja K Mayer; Britta Baumann; Nicole Weisschuh; Ditta Zobor; Gesa-Astrid Hahn; Ulrich Kellner; Sascha Venturelli; Elvir Becirovic; Peter Charbel Issa; Robert K Koenekoop; Günther Rudolph; John Heckenlively; Paul Sieving; Richard G Weleber; Christian Hamel; Xiangang Zong; Martin Biel; Robert Lukowski; Matthias W Seeliger; Stylianos Michalakis; Bernd Wissinger; Peter Ruth
Journal:  J Clin Invest       Date:  2018-11-12       Impact factor: 19.456

7.  Delineating the Molecular and Phenotypic Spectrum of the CNGA3-Related Cone Photoreceptor Disorder in Pakistani Families.

Authors:  Sairah Yousaf; Nabeela Tariq; Zureesha Sajid; Shakeel A Sheikh; Tasleem Kausar; Yar M Waryah; Rehan S Shaikh; Ali M Waryah; Saumil Sethna; Saima Riazuddin; Zubair M Ahmed
Journal:  Genes (Basel)       Date:  2022-03-29       Impact factor: 4.141

8.  Restoration of proper trafficking to the cell surface for membrane proteins harboring cysteine mutations.

Authors:  Angelica Lopez-Rodriguez; Miguel Holmgren
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

9.  A cyclic nucleotide-gated channel mutation associated with canine daylight blindness provides insight into a role for the S2 segment tri-Asp motif in channel biogenesis.

Authors:  Naoto Tanaka; Lucie Delemotte; Michael L Klein; András M Komáromy; Jacqueline C Tanaka
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

10.  Gene Augmentation Therapy for a Missense Substitution in the cGMP-Binding Domain of Ovine CNGA3 Gene Restores Vision in Day-Blind Sheep.

Authors:  Elisha Gootwine; Mazen Abu-Siam; Alexey Obolensky; Alex Rosov; Hen Honig; Tali Nitzan; Andrey Shirak; Raaya Ezra-Elia; Esther Yamin; Eyal Banin; Edward Averbukh; William W Hauswirth; Ron Ofri; Eyal Seroussi
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-03-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.